Sign in Subscribe
Cancer

Breakthrough in Cancer Research: Epitope-guided Antibody Selection for GPCR Modulation and Therapy

Strategic Insights

— 2 min read

Cancer researchers at China Medical University have made a significant breakthrough in the development of antibodies to target cancer cells expressing the CXC chemokine receptor 4 (CXCR4), a key player in various types of cancer. By employing the AlphaFold3 algorithm to predict interaction sites between ligands and GPCRs, the team successfully identified two antibodies, C5 and F4, that inhibit CXCL12 signaling in reporter cell lines. These antibodies also exhibited antibody-dependent cellular cytotoxicity against acute T cell leukemia and B cell lymphoma cell lines. This innovative approach provides a promising avenue for developing effective therapies for cancers linked to CXCR4 expression.

Key Takeaways:

  • Researchers at China Medical University have developed a novel method for epitope-guided selection of CXCR4-targeting antibodies using AlphaFold3 for GPCR modulation and cancer therapy.
  • The study employed a combinatorial library to identify antibodies that bind to CXCR4 and block CXCL12 signaling, exhibiting efficacy in inhibiting cancer cell growth.
  • Two antibodies, C5 and F4, demonstrated significant antibody-dependent cellular cytotoxicity against acute T cell leukemia and B cell lymphoma cells.
  • The research suggests that this approach could lead to the development of effective therapies for cancers associated with CXCR4 expression.
  • The study highlighted the importance of GPCRs in cancer development and the potential therapeutic value of modulating these receptors.
  • The team used AlphaFold3 to predict interaction sites between ligands and GPCRs, demonstrating its potential as a tool for epitope-guided antibody selection.
  • Researchers identified the extracellular loop 2 (ECL2) region as crucial for CXCL12-CXCR4 interactions, indicating its significance in the therapeutic strategy.

Statistics:

  • The research used AlphaFold3 to predict interaction sites between ligands and GPCRs, demonstrating a promising approach for selecting effective antibodies.
  • Two antibodies, C5 and F4, were found to inhibit CXCL12 signaling in reporter cell lines, with potential applications in cancer therapy.
  • Antibody-dependent cellular cytotoxicity (ADCC) was observed against acute T cell leukemia and B cell lymphoma cell lines, highlighting the therapeutic potential of these antibodies.
  • The study demonstrated the effectiveness of this approach in inhibiting cancer cell growth and modulating GPCR functions, offering a new avenue for cancer research.
  • The research highlighted the importance of collaborations and funding from organizations like the National Science and Technology Council Taiwan (NSTC), Ministry of Health and Welfare Taiwan, and Featured Areas Research Center Program by the Ministry of Education (MOE) in Taiwan.

Sources:

  • Original Article Epitope-guided Selection of Cxcr4-targeting Antibodies Using Alphafold3 for Gpcr Modulation and Cancer Therapy. American Journal of Cancer Research, 2025;15(5):2127-2139.
  • China Medical University. Institute for Biochemistry and Molecular Biology. Taichung 406040, Taiwan.
  • Chih-Wei Lin, Srimathi Venkataraman, Yi-Chuan Li, Zi-Wei Hung, Mien-Chie Hung, Yu-Chieh Hsu, Zhuo Yang, Tsung-Tsai, and Kyung Ho Han.

Read more